

Amendments to the Specification

Please amend the paragraph beginning on page 55, line 15, to read as follows:

There are many linking groups known in the art for making antibody-maytansinoid conjugates, including, for example, those disclosed in U.S. Patent No. 5,208,020 (e.g., at column 7, lines 55-67 and at column 8, lines 1-14), or EP Patent 0 425 235 B1, and Chari *et al. Cancer Research* 52: 127-131 (1992). The linking groups include ~~disulfide~~ disulfide groups, thioether groups, acid labile groups, photolabile groups, peptidase labile groups, or esterase labile groups, as disclosed in the above-identified patents, disulfide and thioether groups being preferred. For example, for a compound as illustrated in Figure 3, "R" may be SH or may be SSR₁, where R₁ represents methyl, linear alkyl, branched alkyl, cyclic alkyl, simple or substituted aryl or heterocyclic.